8-K: uniQure's AMT-130 Shows Significant Efficacy in HD Trial

uniQure N.V. announced positive topline data from its pivotal Phase I/II study of AMT-130 for Huntington's disease, meeting primary and key secondary endpoints.

Summary

• Positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington's disease were announced.
• High-dose AMT-130 demonstrated a statistically significant 75% slowing of disease progression as measured by composite Unified Huntington's Disease Rating Scale (cUHDRS) (p=0.003) at 36 months, meeting the primary endpoint.
• High-dose AMT-130 also showed a statistically significant 60% slowing of disease progression as measured by Total Functional Capacity (TFC) (p=0.033) at 36 months, meeting a key secondary endpoint.
• Favorable trends were observed in other secondary endpoint measures of motor and cognitive function, including an 88% slowing in Symbol Digit Modalities Test (SDMT) (p=0.057), a 113% slowing in Stroop Word Reading Test (SWRT) (nominal p=0.002), and a 59% slowing in Total Motor Score (TMS) (nominal p=0.174).
• A mean reduction from baseline in cerebrospinal neurofilament light protein (CSF NfL) of -8.2% was observed, which is a supportive biomarker of neurodegeneration.
• AMT-130 was generally well-tolerated with a manageable safety profile at both doses; no new drug-related serious adverse events have been observed since December 2022.
• The company plans to discuss the AMT-130 data with the FDA at a pre-Biologic License Application (BLA) meeting expected later this year, with the intention of submitting a BLA in the first quarter of 2026.
• The FDA agreed that data from cohorts 1 and 2 could be compared to a propensity score-matched external control from the Enroll-HD natural history data set, which may serve as the primary basis for a BLA submission.

Sentiment

Score: 9

Explanation: The filing reports highly positive, statistically significant topline data from a pivotal Phase I/II study for a severe, unmet medical need, with a clear path to BLA submission and potential market launch. The safety profile is manageable, and the results are considered groundbreaking by experts, indicating a strong positive outlook.

Positives

• Statistically significant 75% slowing of disease progression as measured by cUHDRS (p=0.003) in the high-dose group at 36 months, meeting the primary endpoint.
• Statistically significant 60% slowing of disease progression as measured by TFC (p=0.033) in the high-dose group at 36 months, meeting a key secondary endpoint.
• Favorable trends in other secondary endpoint measures: 88% slowing in SDMT (p=0.057), 113% slowing in SWRT (nominal p=0.002), and 59% slowing in TMS (nominal p=0.174).
• Mean reduction from baseline in CSF NfL of -8.2%, a well-characterized supportive biomarker of neurodegeneration.
• AMT-130 was generally well-tolerated with a manageable safety profile at both doses, with no new drug-related serious adverse events observed since December 2022.
• FDA alignment on the use of propensity score-matched external control data from Enroll-HD for BLA submission.
• AMT-130 has been granted Breakthrough Therapy designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
• Company plans a pre-BLA meeting with the FDA later this year and intends to submit a BLA in the first quarter of 2026, with anticipated U.S. launch later that year, pending approval.

Negatives

• Variable trends were observed in the low-dose group compared to the consistently favorable results in the high-dose group, suggesting a dose-dependent response.

Risks

• Clinical trials of AMT-130 may be unable to demonstrate data sufficient to support further clinical development or regulatory approval.
• Topline data may not be predictive of later data readouts.
• Interactions with regulatory authorities may affect the initiation, timing, and progress of clinical trials and pathways to regulatory approval.
• The measurements being evaluated may not continue to be viewed as robust and sensitive measurements of disease progression.
• Regenerative Medicine Advanced Therapy designation, Breakthrough Therapy designation, or any accelerated pathway, if granted, may not lead to regulatory approval.
• The company's ability to conduct and fund a Phase III or confirmatory study for AMT-130 if needed.
• The company's ability to continue to build and maintain the infrastructure and personnel needed to achieve its goals.
• The company's effectiveness in managing current and future clinical trials and regulatory processes.
• The company's ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials.
• The continued development and acceptance of gene therapies.
• The company's ability to obtain, maintain, and protect its intellectual property.
• The company's ability to fund its operations and to raise additional capital as needed and on acceptable terms.

Future Outlook

uniQure plans to hold a pre-BLA meeting with the FDA later this year, with the intention of submitting a Biologic License Application (BLA) in the first quarter of 2026. Pending regulatory approval, the company anticipates a U.S. launch of AMT-130 later in 2026. The company is also currently enrolling a fourth U.S. based cohort to evaluate high-dose AMT-130 in patients with lower striatal volumes.

Management Comments

• "I am thrilled that this pivotal study of AMT-130 showed statistically significant effects on both cUHDRS and TFC at 36 months, supported by mean CSF NfL remaining below baseline. I believe these groundbreaking data are the most convincing in the field to date and underscore potential disease-modifying effects in Huntingtons disease, where an urgent need persists. These data indicate that AMT-130 has the potential to meaningfully slow disease progression offering long-awaited hope to individuals and families impacted by this devastating disease." Sarah Tabrizi, M.D., FRCP, FRS, FMedSci, Ph.D., professor of clinical neurology, director of the University College London Huntingtons Disease Center and joint head of the department of neurodegenerative disease.
• "We are incredibly excited about these topline results and what they may represent for individuals and families affected by Huntingtons disease. These findings reinforce our conviction that AMT-130 has the potential to fundamentally transform the treatment landscape for Huntingtons disease, while also providing important evidence supporting one-time, precision-delivered gene therapies for the treatment of neurological disorders." Walid Abi-Saab, M.D., chief medical officer of uniQure.

Industry Context

This announcement positions uniQure as a potential leader in the development of gene therapies for neurodegenerative diseases, particularly Huntington's disease, an area with significant unmet medical need. The positive clinical trial results for AMT-130, a one-time gene therapy, represent a substantial advancement in a field where disease-modifying treatments are urgently sought. The FDA's agreement on the statistical analysis plan, including the use of an external control group, suggests a potentially accelerated regulatory pathway, which is critical for rare and severe conditions.

Comparison to Industry Standards

• The study compared AMT-130 clinical endpoints to a propensity score-matched external control derived from the Enroll-HD natural history data set (n=940 for high dose; n=626 for low dose).
• Various other supportive analyses of the AMT-130 high-dose treatment group, including those using a propensity score-weighted external control and comparisons to the TRACK-HD and PREDICT-HD datasets, were consistent with the primary analysis.
• Sarah Tabrizi, M.D., a leading expert in Huntington's disease, stated that these data are "the most convincing in the field to date" and underscore potential disease-modifying effects.

Stakeholder Impact

• **Shareholders**: Highly positive news, likely to increase investor confidence and potentially share price due to significant clinical success and a clear regulatory path for a major pipeline asset.
• **Patients with Huntington's Disease**: Offers "long-awaited hope" for a disease-modifying treatment where none currently exist, potentially transforming their treatment landscape and improving quality of life.
• **Employees**: Positive impact on morale and company trajectory, reinforcing the value and potential impact of their work in gene therapy development.
• **Regulatory Authorities (FDA)**: Engaged in discussions and aligned on statistical plans, indicating a collaborative and structured approach to potential approval, which could streamline the review process.

Next Steps

• Host an investor conference call and webcast on September 24, 2025, to discuss the updates.
• Hold a pre-BLA meeting with the FDA later this year.
• Submit a Biologic License Application (BLA) in the first quarter of 2026.
• Continue enrolling a fourth U.S. based cohort for high-dose AMT-130 in patients with lower striatal volumes.
• Anticipate a U.S. launch of AMT-130 later in 2026, pending regulatory approval.

Key Dates

Recommendation

The announcement of statistically significant positive topline data from a pivotal Phase I/II study for AMT-130 in Huntington's disease, meeting both primary and key secondary endpoints, is a major de-risking event for uniQure. The FDA's agreement on the use of external control data for BLA submission and the company's clear timeline for BLA submission in Q1 2026 and potential U.S. launch in late 2026 indicate a strong and accelerated path to market for a potentially disease-modifying gene therapy in an area of high unmet medical need. The manageable safety profile further strengthens the investment case. This news significantly enhances the company's valuation and future revenue potential, making it a strong buy for investors.

Keywords

Gene therapy, Huntington's disease, AMT-130, Clinical trial, Neurodegenerative, FDA, BLA, cUHDRS, TFC, CSF NfL, uniQure